Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epigenetic Regulation01:46

Epigenetic Regulation

31.3K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

400
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
400
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

238
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
238
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

273
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
273
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

343
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
343

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

o-Coumaric Acid Promotes Angiogenesis and Wound Healing Under Hyperglycemic Stress Through Modulation of Oxidative Stress and Inflammation.

Chemistry & biodiversity·2026
Same author

Preparation, characterization, and pre-clinical evaluation of acarbose-guar gum solid dispersions in diabetic rats.

International journal of biological macromolecules·2026
Same author

Epigenetic age acceleration in diabetes and its clinical implications.

Diabetes research and clinical practice·2026
Same author

Guar gum macromolecule-based nanoformulation of syringic acid for enhanced diabetic wound healing: Box-Behnken optimization and in vitro evaluation.

International journal of biological macromolecules·2026
Same author

α-Glucosidase inhibitor: identifying key targets and mechanisms in type 2 diabetes.

3 Biotech·2026
Same author

AMPK as a central regulator of metabolic memory: mechanisms and therapeutic opportunities.

Journal of diabetes and metabolic disorders·2026

Related Experiment Video

Updated: Aug 31, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

636

Targeting epigenetic regulators for treating diabetic nephropathy.

Kriti Kushwaha1, Sourbh Suren Garg2, Jeena Gupta2

  • 1Department of Biotechnology, School of Bioengineering and Bioscience, Lovely Professional University, Phagwara, Punjab, India.

Biochimie
|August 19, 2022
PubMed
Summary

Epigenetic changes like DNA methylation and histone modifications worsen diabetic kidney disease. Understanding these epigenetic mechanisms offers new therapeutic strategies for diabetic nephropathy.

Keywords:
DiabetesDiabetic nephropathyEpigeneticsKidney failure

More Related Videos

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K
Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
10:28

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

6.5K

Related Experiment Videos

Last Updated: Aug 31, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

636
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K
Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
10:28

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

6.5K

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Diabetes mellitus is a leading cause of chronic kidney disease.
  • Diabetic nephropathy (DN) involves complex genetic and environmental factors.
  • Vascular complications and end-stage renal disorder (ESRD) are major concerns in diabetic patients.

Purpose of the Study:

  • To review the role of epigenetic modifications in the progression of diabetic nephropathy.
  • To highlight current strategies for ameliorating DN through epigenetic interventions.

Main Methods:

  • Review of current literature on epigenetics in diabetic kidney disease.
  • Analysis of post-translational histone modifications (PTHMs), DNA methylation (DNAme), and microRNAs (miRNAs) in DN.
  • Examination of the impact of hyperglycemia on epigenetic mechanisms in renal cells.

Main Results:

  • Aberrant PTHMs, DNAme, and miRNAs are key epigenetic drivers of DN.
  • Hyperglycemia-induced epigenetic alterations lead to fibrosis, extracellular matrix (ECM) accumulation, reactive oxygen species (ROS) production, and renal injury.
  • Histone acetylation (HAc) and deacetylation (HDAC) are significantly implicated in kidney disorders.

Conclusions:

  • Epigenetic modifications play a crucial role in the pathogenesis and progression of diabetic nephropathy.
  • Targeting epigenetic mechanisms presents a promising therapeutic avenue for managing DN and preventing ESRD.